Lupus Therapeutic Market Is Estimated To Witness High Growth Owing To Increasing Disease Prevalence
Market Overview:
Lupus therapeutic products are used for the treatment of systemic lupus erythematosus (SLE), commonly known as lupus. SLE is a chronic autoimmune disease that causes inflammation and tissue damage in various parts of the body including joints, skin kidneys, blood cells, brain, heart and lungs. The disease affects approximately 1.5 million people in the U.S. and drugs therapies help reduce disease symptoms and organ damage.
Market Dynamics:
The lupus therapeutic market is driven by increasing prevalence of SLE globally. According to estimates, around 1.5 million Americans and at least 5 million people worldwide have lupus. It is most common in women aged 15 to 44, with 90% of people with the disease being women. Furthermore, rising R&D investments by key players for development of novel and targeted therapies and rising awareness about disease management are also fueling market growth. However, high treatment costs, availability of alternative treatment methods and lack of FDA approved drugs for certain indications restrain the market growth.
The lupus therapeutic market dynamics include drivers such as increasing disease prevalence globally. The autoimmune disease affects approximately 1.5 million people in the U.S. Rising investments in R&D for novel and targeted therapies is also boosting the market. However, high treatment costs and availability of alternative treatment methods poses challenge. Strict FDA regulations for drug approval further restrains market growth.
Arabic
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian